| 摘要 |
The present invention concerns the enhancement of cell survival and osteogenic potential of bone graft by ex vivo treatment with a Wnt polypeptide, such as a liposomal Wnt polypeptide. In particular, the invention concerns the ex vivo treatment of bone grafts with a human Wnt3a protein, preferably liposomal human Wnt3a (LWnt3a). |
